成人B细胞急性淋巴细胞白血病CAR-T治疗的系统综述
该系统综述评估了CAR-T治疗成人复发/难治B-ALL的疗效与毒性,纳入16项研究共489例患者。CAR-T输注后4周平均完全缓解率81%,MRD阴性缓解率81%;中位随访24个月,12个月无进展生存率和总生存率分别为37%和57%。任何级别细胞因子释放综合征发生率82%,≥3级27%;任何级别神经毒性34%,≥3级14%。
要点
- 成人r/r B-ALL患者CAR-T治疗后4周完全缓解率和MRD阴性率均达81%。
- 12个月PFS为37%(95%CI 26-48),OS为57%(95%CI 49-65),复发率40.3%。
- 任何级别CRS发生率82%(95%CI 61-95),≥3级CRS 27%(95%CI 18-36)。
核心结论
- CAR-T疗法在成人r/r B-ALL中实现高早期缓解率,显著优于传统挽救化疗,但复发常见且持久缓解仍是挑战。
研究设计与样本
- 系统综述,检索MEDLINE、Embase和Cochrane Library的前瞻性干预研究,纳入≥5例且中位入组年龄≥18岁的已发表研究。
- 共评估2566条记录,最终纳入16项研究共489例患者,使用改良的Institute of Health Economics工具评估偏倚风险。
主要发现
- CAR-T输注后4周平均完全缓解率为81%,可测量残留病(MRD)阴性缓解率为81%。
- 中位随访24个月,12个月无进展生存率(PFS)为37%(95%CI 26-48),总生存率(OS)为57%(95%CI 49-65)。
- 复发率40.3%,其中73.2%的复发保留了靶抗原。
- 任何级别细胞因子释放综合征(CRS)发生率为82%(95%CI 61-95),≥3级CRS为27%(95%CI 18-36)。
- 任何级别神经毒性发生率为34%(95%CI 24-47),≥3级神经毒性为14%(95%CI 1-25)。
临床怎么用
- CAR-T可作为成人r/r B-ALL的有效挽救治疗选择,需关注高缓解率后的复发风险及CRS和神经毒性管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed treatment paradigms for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) in children and younger adults. We performed a systematic review to investigate the published literature on efficacy and toxicity of CAR-T therapy in adults with r/r B-ALL. We searched MEDLINE, Embase, and the Cochrane Library for prospective interventional studies and included published studies of ≥5 patients with median age at enrollment of ≥18 years. Risk of bias was assessed with a modified Institute of Health Economics tool. A total of 2566 records were assessed; 16 studies involving 489 patients were included in the final analysis. The mean complete remission (CR) rate was 81% and the measurable residual disease (MRD)-negative remission rate was 81% at 4 weeks after CAR-T infusion. With median follow-up across studies of 24 months, the cumulative 12-month probabilities of progression-free survival (PFS) and overall survival (OS) were 37% (95% CI, 26-48) and 57% (95% CI, 49-65), respectively. Relapse occurred in 40.3% of cases; target antigen was retained in 73.2% of relapses. Across studies, any grade of cytokine release syndrome (CRS) occurred in 82% of patients (95% CI, 61-95) and grade 3 or higher CRS in 27% (95% CI, 18-36). Neurotoxicity of any grade occurred in 34% of patients (95% CI, 24-47) and grade 3 or higher in 14% (95% CI, 1-25). In summary, CAR-T therapy achieves high early remission rates in adults with r/r B-ALL and represents a significant improvement over traditional salvage chemotherapy. Relapses are common and durable response remains a challenge.
引用
- Grover P, Veilleux O, Tian L, et al. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2022. PMID: 34610109. doi:10.1182/bloodadvances.2020003482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。